Rankings
▼
Calendar
JAZZ (Jazz Pharmaceuticals plc) Stock Financials & Earnings | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
Mkt Cap
$12B
Healthcare
·
Biotechnology
·
🇮🇪 Ireland
·
NASDAQ
Revenue (TTM)
$4.3B
Net Income (TTM)
-$356M
EPS (TTM)
-$5.84
Free Cash Flow (TTM)
$1.2B
Gross Margin
88.2%
Op. Margin
5.3%
Net Margin
-8.3%
FCF Margin
29.2%
P/S Ratio (TTM)
2.7x
P/E Ratio (TTM)
—
YoY Rev Growth
+4.9%
Employees
—
Earnings Reports
▶
Q4 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$893M
$764M
$126M
Q2 23
$957M
$860M
$158M
Q3 23
$972M
$870M
$172M
Q4 23
$1.0B
$905M
$122M
Q1 24
$902M
$806M
$66M
Q2 24
$1.0B
$914M
$199M
Q3 24
$1.1B
$943M
$260M
Q4 24
$1.1B
$959M
$191M
Q1 25
$898M
$793M
-$56M
Q2 25
$1.0B
$929M
-$686M
Q3 25
$1.1B
$868M
$58M
Q4 25
$1.2B
$1.2B
$909M
marketcaparena.com
Revenue Breakdown
JAZZ
Jazz Pharmaceuticals plc
Revenue Breakdown
Q4 2025
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
3.1x
—
Q2 23
3.1x
—
Q3 23
3.0x
143.2x
Q4 23
3.0x
27.9x
Q1 24
3.0x
35.0x
Q2 24
3.0x
29.3x
Q3 24
2.9x
25.0x
Q4 24
2.8x
20.6x
Q1 25
2.8x
24.0x
Q2 25
2.8x
—
Q3 25
2.8x
—
Q4 25
2.7x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
$321M
$317M
Q2 23
$297M
$291M
Q3 23
$307M
$303M
Q4 23
$167M
$139M
Q1 24
$267M
$260M
Q2 24
$331M
$324M
Q3 24
$399M
$388M
Q4 24
$399M
$385M
Q1 25
$430M
$391M
Q2 25
$89M
$101M
Q3 25
$475M
$459M
Q4 25
$363M
$297M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$4M
Q2 23
$6M
Q3 23
$4M
Q4 23
$28M
Q1 24
$7M
Q2 24
$7M
Q3 24
$11M
Q4 24
$13M
Q1 25
$39M
Q2 25
$12M
Q3 25
$15M
Q4 25
$66M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+9.7%
+5.6%
Q2 23
+2.6%
-5.6%
Q3 23
+3.3%
-12.7%
Q4 23
+4.1%
-28.0%
Q1 24
+1.0%
+9.0%
Q2 24
+6.9%
+3.1%
Q3 24
+8.5%
-0.6%
Q4 24
+7.5%
+0.9%
Q1 25
-0.5%
+14.1%
Q2 25
+2.1%
+110.1%
Q3 25
+6.7%
+34.5%
Q4 25
+10.1%
-67.8%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$56M
6.3%
Q2 23
$61M
6.4%
Q3 23
$56M
5.8%
Q4 23
$53M
5.2%
Q1 24
$61M
6.8%
Q2 24
$57M
5.5%
Q3 24
$60M
5.7%
Q4 24
$70M
6.5%
Q1 25
$68M
7.5%
Q2 25
$65M
6.2%
Q3 25
$88M
7.8%
Q4 25
$200M
16.7%
marketcaparena.com
OpEx Breakdown
R&D
SG&A
Quarter
R&D
SG&A
Q1 23
$189M
$298M
Q2 23
$209M
$341M
Q3 23
$234M
$308M
Q4 23
$217M
$396M
Q1 24
$223M
$352M
Q2 24
$221M
$339M
Q3 24
$200M
$326M
Q4 24
$241M
$369M
Q1 25
$181M
$514M
Q2 25
$190M
$358M
Q3 25
$241M
$531M
Q4 25
$171M
$406M
marketcaparena.com
Revenue Segments
Defitelio/Defibrotide
Epidiolex/Epidyolex
High Sodium AG Oxybate Product Royalty Revenue
Other Products
Other Royalty And Contract Revenues
Rylaze/Enrylaze
Sativex
Vyxeos
Xyrem
Xywav
Zepzelca
Ziihera
Quarter
Defitelio/Defibrotide
Epidiolex/Epidyolex
High Sodium AG Oxybate Product Royalty Revenue
Other Products
Other Royalty And Contract Revenues
Rylaze/Enrylaze
Sativex
Vyxeos
Xyrem
Xywav
Zepzelca
Ziihera
Q1 23
$39M
$189M
$2M
$3M
$6M
$86M
$7M
$37M
$178M
$278M
$67M
—
Q2 23
$46M
$202M
$6M
$3M
$5M
$102M
$3M
$34M
$160M
$327M
$70M
—
Q3 23
$48M
$214M
$29M
$3M
$5M
$105M
$5M
$30M
$125M
$332M
$78M
—
Q1 24
$48M
$199M
$50M
$4M
$10M
$103M
$3M
$32M
$64M
$315M
$75M
—
Q2 24
$45M
$247M
$54M
$3M
$6M
$108M
$6M
$43M
$62M
$368M
$81M
—
Q3 24
$66M
$252M
$58M
$2M
$7M
$99M
$5M
$34M
$58M
$388M
$86M
—
Q4 24
$58M
$275M
$55M
$3M
—
$101M
$5M
$53M
$49M
$401M
$78M
—
Q1 25
$41M
$218M
$49M
$5M
$9M
$94M
$5M
$30M
$37M
$345M
$63M
$2M
Q2 25
$48M
$252M
$54M
$4M
$6M
$101M
$5M
$45M
$35M
$415M
$75M
$6M
Q3 25
$52M
$303M
$53M
$2M
$9M
$100M
$5M
$38M
$36M
$431M
$79M
$8M
Q4 25
$59M
$287M
$56M
$3M
—
$108M
$2M
$35M
$38M
$465M
$90M
$9M
marketcaparena.com
Revenue by Geography
Europe
Other Countries
United States
Quarter
Europe
Other Countries
United States
Q1 23
$66M
$17M
$810M
Q2 23
$59M
$13M
$885M
Q3 23
$69M
$19M
$885M
Q1 24
$71M
$22M
$808M
Q2 24
$82M
$17M
$925M
Q3 24
$77M
$24M
$954M
Q4 24
$82M
$33M
$974M
Q1 25
$84M
$16M
$798M
Q2 25
$83M
$27M
$936M
Q3 25
$86M
$19M
$1.0B
Q4 25
$88M
$33M
$1.1B
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$1.2B
$0
$1.2B
Q2 23
$1.3B
$80M
$1.4B
Q3 23
$1.3B
$250M
$1.6B
Q4 23
$1.5B
$120M
$1.6B
Q1 24
$1.4B
$375M
$1.8B
Q2 24
$1.4B
$625M
$2.0B
Q3 24
$2.2B
$400M
$2.6B
Q4 24
$2.4B
$580M
$3.0B
Q1 25
$1.9B
$710M
$2.6B
Q2 25
$1.2B
$480M
$1.7B
Q3 25
$1.2B
$810M
$2.0B
Q4 25
$1.4B
$1.1B
$2.4B
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
74M
+17.0%
Q2 23
74M
-0.3%
Q3 23
71M
-3.1%
Q4 23
70M
-2.3%
Q1 24
63M
-10.2%
Q2 24
70M
+11.3%
Q3 24
63M
-9.3%
Q4 24
62M
-2.6%
Q1 25
61M
-0.9%
Q2 25
61M
+0.4%
Q3 25
62M
+0.7%
Q4 25
61M
-1.0%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
$1M
870
FY 15
$1M
910
FY 16
$1M
1K
FY 17
$1M
1K
FY 18
$1M
1K
FY 19
$1M
2K
FY 20
$1M
2K
FY 21
$967K
3K
FY 22
$1M
3K
FY 23
$1M
3K
FY 24
$1M
3K
FY 25
$427K
10K
marketcaparena.com